Krogerus advised Curium, a Franco-Irish nuclear medicine specialist on its acquisition of Finnish radiopharmaceuticals company MAP Medical Technologies Oy.
The acquisition of MAP Medical will further expand Curium’s footprint in Europe, providing direct access to Nordic and Baltic countries for its broad portfolio of life saving diagnostic solutions.
MAP Medical operates three GMP manufacturing sites across Finland, two in Helsinki and one in Tikkakoski, and has been supplying critical radiopharmaceutical agents to customers across Nordics and Baltics since 1991. The Company employs c.50 people and offers a range of PET diagnostic agents. It is also a distributor of Curium’s SPECT product portfolio in Finland.
The Krogerus team was led by partner Mika Ståhlberg, who was assisted by senior associate Anna Metso.